Travis joined Abingworth/Carlyle in November 2025, bringing more than 20 years of life sciences investing and executive experience. Within the Abingworth business, he works with the Clinical Co-Development team, evaluating new opportunities and supporting existing investments. In Carlyle’s US Buyout business, Travis focuses on private equity transactions in the healthcare space, with a particular focus in pharma products and services.
Previously, Travis was a Growth Partner with Flagship Pioneering, where he held board and leadership roles on development and commercial-stage biotech companies, including Valo Health, Mirai Bio, and Harbinger Health.
Prior to Flagship, Travis was the Managing Partner of Gurnet Point Capital, a private equity fund involved with public market buyouts, including the privatization of commercial biotech companies. During his Gurnet Point tenure, he also served as a board member of Boston Pharmaceuticals, focusing on the development of efimosfermin for MASH.
Travis was previously the CEO of Stealth BioTherapeutics, a mitochondrial-focused company, developing Forzinity for Barth syndrome, in parallel, he was a member of the venture capital team for Morningside, where he worked on BioVex, Aduro (merged with Chinook Therapeutics), Liquidia, ACD, and Apellis.
Travis holds Chemical Engineering and Law degrees, both from the University of Wisconsin.
